Tesamorelin is a stabilised GHRH analog that resists DPP-4 cleavage via an N-terminal trans-3-hexenoic acid modification. This is the full New Zealand research profile for the tesamorelin peptide.
The tesamorelin peptide is a synthetic GHRH analog engineered by adding a trans-3-hexenoic acid moiety to the N-terminus of GHRH(1-44). That single modification blocks cleavage by dipeptidyl peptidase-4 (DPP-4) — the enzyme that rapidly clears native GHRH — while preserving receptor-binding geometry. Tesamorelin is one of the most extensively characterised long-acting GHRH analogs in the published research literature.
Tesamorelin peptide structure
| Attribute | Specification |
|---|---|
| Backbone | GHRH 1-44 |
| Modification | N-terminal trans-3-hexenoic acid |
| Molecular weight | ~5,196 Da |
| Receptor target | GHRH receptor (GHRHR) |
| Enzymatic resistance | Resistant to DPP-4 cleavage |
| Documented purity spec | ≥ 98% HPLC |
Tesamorelin vs other GHRH-family references
| Compound | Length | Enzyme resistance | Kinetic role |
|---|---|---|---|
| Sermorelin | GHRH 1-29 | None | Short / pulsatile |
| Mod GRF 1-29 | GHRH 1-29 + subs | DPP-4 resistant | Short / stabilised |
| CJC-1295 DAC | GHRH 1-29 + DAC | DPP-4 + albumin binding | Multi-day |
| Tesamorelin | GHRH 1-44 + hexenoic acid | DPP-4 resistant | Extended full-length reference |
Reference published daily dose
| Reference daily dose | Published research context |
|---|---|
| 2 mg | Adult research populations |
Why tesamorelin is documented in research
- Full-length GHRH backbone (1-44) rather than the truncated 1-29 fragment.
- DPP-4 resistance produces a longer, more measurable exposure curve.
- Extensive published clinical characterisation as a reference GHRH analog.
- Frequently used as a comparator for newer stabilised GHRH candidates.
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Tesamorelin peptide FAQ
What is the tesamorelin peptide?
Tesamorelin is a synthetic GHRH(1-44) analog with an N-terminal trans-3-hexenoic acid modification that resists DPP-4 cleavage, extending its published exposure profile relative to sermorelin.
How is tesamorelin different from sermorelin?
Sermorelin is the unmodified GHRH 1-29 fragment; tesamorelin is the full GHRH 1-44 sequence with an N-terminal hexenoic acid modification that provides enzymatic stability.
How is tesamorelin different from CJC-1295 DAC?
Both are long-acting GHRH references. Tesamorelin achieves stability through DPP-4 resistance; CJC-1295 DAC achieves it through covalent albumin binding via a maleimide linker.
Where can New Zealand researchers buy the tesamorelin peptide?
Kiwi Peps supplies research-grade tesamorelin at ≥98% HPLC purity with third-party COA and same-day domestic dispatch. Research use only.
